OrbiMed Advisors ITOS Position
Exited7-Fund ConvergenceOrbiMed Advisors exited their position in iTeos Therapeutics SA (ITOS) in Q3 2025, after holding the stock for 2 quarters.
The position was first reported in Q2 2025 and has been tracked across 2 quarterly 13F filings.
ITOS is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About iTeos Therapeutics SA
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
Full company profile →OrbiMed Advisors ITOS Position History
Frequently Asked Questions
Does OrbiMed Advisors own ITOS?
No. OrbiMed Advisors exited their position in iTeos Therapeutics SA (ITOS) in Q3 2025. They previously held the stock for 2 quarters.
How many hedge funds own ITOS?
7 specialist biotech hedge funds currently hold ITOS, including EcoR1 Capital, Boxer Capital, RA Capital Management and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy ITOS?
OrbiMed Advisors's position in ITOS was first reported in Q2 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's ITOS position increasing or decreasing?
OrbiMed Advisors completely exited their ITOS position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ITOSCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →